Response to Comments: Genomic Sequence Analysis Panels in the Treatment of Myelodysplastic Syndromes

This document is a response to comments on the Genomic Sequence Analysis Panels LCD for the treatment of myelodysplastic syndromes. It announces the official notice period beginning October 16, 2017 and that the final LCD will become effective December 1, 2017; the response contains no clinical coverage criteria, indications, limitations, documentation requirements, or frequency limits.